Angiosarcoma and Undifferentiated Pleomorphic Sarcoma: Propranolol and Pembrolizumab Study

We are studying the effects of a new treatment combining propranolol and pembrolizumab for patients with advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma. The goal is to see if this combination improves survival and quality of life.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Keytruda
Keytruda is a cancer medicine that helps the immune system find and fight tumor cells.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Pembrolizumab
Pembrolizumab is a substance that helps the immune system recognize and attack certain cancers by blocking a protein called PD-1.
Propranolol Hydrochloride
Propranolol hydrochloride is a beta-blocker that lowers heart rate and blood pressure to treat heart-related conditions and reduce physical anxiety symptoms.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Aarhus Universitetshospital
Department of Oncology
Århus, Denmark
Region Hovedstaden
Department of Oncology
Rødovre, Denmark
Oslo University Hospital HF
Department of Oncology
Oslo, Norway
Sponsor: Region Hovedstaden
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.